Clinical Trial Update: CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma [Phase 2]

View source ↗

Summary

This update reports the termination of a Phase 2 study of CYT003-QbG10, a TLR9 agonist, for treatment of uncontrolled moderate to severe allergic asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma
• Asthma

Drugs mentioned

• CYT003-QbG10

Snippet

Sponsor: Cytos Biotechnology AG | Conditions: Moderate to Severe Allergic Asthma | Phase 2 | Status: TERMINATED